Literature DB >> 29523541

Peli1 Modulates the Subcellular Localization and Activity of Mdmx.

Dawei Li1, Omid Tavana1, Shao-Cong Sun2, Wei Gu3.   

Abstract

Mdm2 and Mdmx, both major repressors of p53 in human cancers, are predominantly localized to the nucleus and cytoplasm, respectively. The mechanism by which subcellular localization of Mdmx is regulated remains unclear. In this study, we identify the E3 ligase Peli1 as a major binding partner and regulator of Mdmx in human cells. Peli1 bound Mdmx in vitro and in vivo and promoted high levels of ubiquitination of Mdmx. Peli1-mediated ubiquitination was degradation-independent, promoting cytoplasmic localization of Mdmx, which in turn resulted in p53 activation. Consistent with this, knockdown or knockout Peli1 in human cancer cells induced nuclear localization of Mdmx and suppressed p53 activity. Myc-induced tumorigenesis was accelerated in Peli1-null mice and associated with downregulation of p53 function. Clinical samples of human cutaneous melanoma had decreased Peli1 expression, which was associated with poor overall survival. Together, these results demonstrate that Peli1 acts as a critical factor for the Mdmx-p53 axis by modulating the subcellular localization and activity of Mdmx, thus revealing a novel mechanism of Mdmx deregulation in human cancers.Significance: Peli1-mediated regulation of Mdmx, a major inhibitor of p53, provides critical insight into activation of p53 function in human cancers. Cancer Res; 78(11); 2897-910. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29523541      PMCID: PMC5984691          DOI: 10.1158/0008-5472.CAN-17-3531

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  44 in total

Review 1.  Negative auto-regulators trap p53 in their web.

Authors:  Xiang Zhou; Bo Cao; Hua Lu
Journal:  J Mol Cell Biol       Date:  2017-02-01       Impact factor: 6.216

Review 2.  The roles of Pellino E3 ubiquitin ligases in immunity.

Authors:  Paul N Moynagh
Journal:  Nat Rev Immunol       Date:  2014-01-21       Impact factor: 53.106

Review 3.  The Mdm network and its regulation of p53 activities: a rheostat of cancer risk.

Authors:  Christine M Eischen; Guillermina Lozano
Journal:  Hum Mutat       Date:  2014-03-06       Impact factor: 4.878

4.  Pellino 1 promotes lymphomagenesis by deregulating BCL6 polyubiquitination.

Authors:  Hye-Young Park; Heounjeong Go; Ha Rim Song; Suhyeon Kim; Geun-Hyoung Ha; Yoon-Kyung Jeon; Ji-Eun Kim; Ho Lee; Hyeseong Cho; Ho Chul Kang; Hee-Young Chung; Chul-Woo Kim; Doo Hyun Chung; Chang-Woo Lee
Journal:  J Clin Invest       Date:  2014-10-08       Impact factor: 14.808

Review 5.  p53 ubiquitination: Mdm2 and beyond.

Authors:  Christopher L Brooks; Wei Gu
Journal:  Mol Cell       Date:  2006-02-03       Impact factor: 17.970

Review 6.  Germline TP53 mutations and Li-Fraumeni syndrome.

Authors:  J M Varley
Journal:  Hum Mutat       Date:  2003-03       Impact factor: 4.878

7.  Peli1 facilitates TRIF-dependent Toll-like receptor signaling and proinflammatory cytokine production.

Authors:  Mikyoung Chang; Wei Jin; Shao-Cong Sun
Journal:  Nat Immunol       Date:  2009-09-06       Impact factor: 25.606

8.  Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development.

Authors:  Tamara Terzian; Yongxing Wang; Carolyn S Van Pelt; Neil F Box; Elisabeth L Travis; Guillermina Lozano
Journal:  Mol Cell Biol       Date:  2007-05-25       Impact factor: 4.272

Review 9.  Reactivation of p53 as therapeutic intervention for malignant melanoma.

Authors:  Aart G Jochemsen
Journal:  Curr Opin Oncol       Date:  2014-01       Impact factor: 3.645

10.  MDM4 is a key therapeutic target in cutaneous melanoma.

Authors:  Agnieszka Gembarska; Flavie Luciani; Clare Fedele; Elisabeth A Russell; Michael Dewaele; Stéphanie Villar; Aleksandra Zwolinska; Sue Haupt; Job de Lange; Dana Yip; James Goydos; Jody J Haigh; Ygal Haupt; Lionel Larue; Aart Jochemsen; Hubing Shi; Gatien Moriceau; Roger S Lo; Ghanem Ghanem; Mark Shackleton; Federico Bernal; Jean-Christophe Marine
Journal:  Nat Med       Date:  2012-07-22       Impact factor: 53.440

View more
  8 in total

1.  β-Arrestin-1 inhibits glucocorticoid receptor turnover and alters glucocorticoid signaling.

Authors:  Maria G Petrillo; Robert H Oakley; John A Cidlowski
Journal:  J Biol Chem       Date:  2019-06-05       Impact factor: 5.157

2.  MDMX inhibits casein kinase 1α activity and stimulates Wnt signaling.

Authors:  Qingling Huang; Lihong Chen; Ernst Schonbrunn; Jiandong Chen
Journal:  EMBO J       Date:  2020-06-08       Impact factor: 11.598

3.  Low-level expression of necroptosis factors indicates a poor prognosis of the squamous cell carcinoma subtype of non-small-cell lung cancer.

Authors:  Jun Hyeok Lim; Sekyung Oh; Lucia Kim; Young Ju Suh; Yu-Jin Ha; Jung Soo Kim; Hyun-Jung Kim; Mi Hwa Park; Young Sam Kim; Yunjung Cho; Seung Min Kwak; Hong Lyeol Lee; You-Sun Kim; Jeong-Seon Ryu
Journal:  Transl Lung Cancer Res       Date:  2021-03

Review 4.  Acquired Glucocorticoid Resistance Due to Homologous Glucocorticoid Receptor Downregulation: A Modern Look at an Age-Old Problem.

Authors:  Lee-Maine L Spies; Nicolette J D Verhoog; Ann Louw
Journal:  Cells       Date:  2021-09-24       Impact factor: 6.600

Review 5.  The Emerging Roles of Pellino Family in Pattern Recognition Receptor Signaling.

Authors:  E Zhang; Xia Li
Journal:  Front Immunol       Date:  2022-02-07       Impact factor: 7.561

6.  RPRM negatively regulates ATM levels through its nuclear translocation on irradiation mediated by CDK4/6 and IPO11.

Authors:  Yarui Zhang; Guomin Ou; Zhujing Ye; Zhou Zhou; Qianlin Cao; Mengting Li; Jingdong Wang; Jianping Cao; Hongying Yang
Journal:  iScience       Date:  2022-09-13

Review 7.  The long and the short of it: the MDM4 tail so far.

Authors:  Sue Haupt; Javier Octavio Mejía-Hernández; Reshma Vijayakumaran; Simon P Keam; Ygal Haupt
Journal:  J Mol Cell Biol       Date:  2019-03-01       Impact factor: 6.216

8.  Inhibition of MELK produces potential anti-tumour effects in bladder cancer by inducing G1/S cell cycle arrest via the ATM/CHK2/p53 pathway.

Authors:  Song Chen; Qiang Zhou; Zicheng Guo; Yejinpeng Wang; Lu Wang; Xuefeng Liu; Mengxin Lu; Lingao Ju; Yu Xiao; Xinghuan Wang
Journal:  J Cell Mol Med       Date:  2019-12-10       Impact factor: 5.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.